First ‘lab in lab’ sites operational in Canada and the US following official launch of O2Vent® Optima oral device in the US
Key points:
-
The first ‘lab in lab’ customer clinical delivery sites have been launched in the US and Canada, with revenue expected in the fourth quarter of calendar 2019
-
Oventus formally launches O2Vent Optima oral device in US sleep and dental channels
-
Launch enabled by FDA clearance being granted to O2Vent Optima in September
-
Further agreements expected to be announced throughout the remainder of calendar 2019 and into calendar 2020
-
Oventus strongly positioned to invest in growth and scale sales following its recent Placement and Entitlement Offer which raised a total of A$9.3m
Brisbane, Australia 11 October 2019: Oventus Medical Ltd or the Company (ASX: OVN) is pleased to announce that it has launched the first five ‘lab in lab’ sites in the US and Canada to coincide with the formal launch of the O2Vent Optima oral device within US sleep and dental channels. These launches closely follow the O2Vent Optima’s September regulatory clearance from the US Food and Drug Administration (FDA).
For further information please download the attached PDF:
Download this document
